Press Release Headline – Date Published

• SITC Publishes Clinical Practice Guideline on Immune Effector Cell-related Adverse Events – 12/18/20
• SITC Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Acute Leukemia – 11/17/20
• Society for Immunotherapy of Cancer Announces Creation of Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund and Names Inaugural Recipient 
• Society for Immunotherapy of Cancer to Host Third Annual Cancer Immunotherapy Winter School
• Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Multiple Myeloma – 8/3/20
• Oncology News Burst from FDA: Atezolizumab – 7/31/20
• Oncology News Burst from FDA: Avelumab – 7/1/20
• Oncology News Burst from FDA: Pembrolizumab – 6/30/20
• Oncology News Burst from FDA: Pembrolizumab – 6/24/20
• Oncology News Burst from FDA: Pembrolizumab – 6/17/20
• Oncology News Burst from FDA: Gemtuzumab Ozogamicin – 6/16/20
• Oncology News Burst from FDA: Nivolumab – 6/11/20
• Society for Immunotherapy of Cancer Announces Recipients of 2020 Cancer Immunotherapy Fellowships and Award – 6/1/20
• Oncology News Burst from FDA: Atezolizumab plus Bevacizumab – 6/1/20
• Society for Immunotherapy of Cancer Celebrates Cancer Immunotherapy Month™ – 6/1/20
• Oncology News Burst from FDA: Nivolumab plus Ipilimumab – 5/27/20
• Oncology News Burst from FDA: Atezolizumab – 5/19/20
• Oncology News Burst from FDA: Nivolumab plus Ipilimumab – 5/15/20
• Oncology News Burst from FDA: Daratumumab and Hyaluronidase-fihj – 5/1/20
• Oncology News Burst from FDA: Pembrolizumab – 4/29/20
• SITC Announces Three Recipients of the 2020 Richard V. Smalley, MD, Memorial Award and Lectureship – 4/23/20
• Oncology News Burst from FDA: Sacituzumab Govitecan-hziy – 4/22/2020
• Oncology News Burst from FDA: Ibrutinib – 4/21/2020
• Society for Immunotherapy of Cancer Releases Perspective Paper on Investigational Therapies for COVID-19 Patients with Severe Inflammatory Resonse – 4/21/2020
• Oncology News Burst from FDA: Durvalumb – 3/30/2020
• Society for Immunotherapy of Cancer Advocates for Expanded Access to Anti-IL-6 Therapies for Critically Ill Patients – 3/25/20
• Society for Immunotherapy of Cancer urges scientific journals to grant open access to COVID-19 publications – 3/23/20
• Coronavirus (COVID-19) Update: FDA Issues Guidance for Conducting Clinical Trials – 3/20/20
• Oncology News Burst from FDA: Nivolumab and Ipilimumab Combination – 3/11/20
• Oncology News Burst from FDA: Isatuximab-Irfc – 3/2/20
• SITC to Host Leadership Institute Focusing on Professional Development of Women in Cancer Immunotherapy – 1/27/20
• Oncology News Burst from FDA: Pembrolizumab – 1/8/20